

**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 39053

**Manuscript Type:** REVIEW

**Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?**

Moreno-Cubero E *et al.* NA cessation in CHB

Elia Moreno-Cubero, Robert T Sánchez del Arco, Julia Peña-Asensio, Eduardo Sanz de Villalobos, Joaquín Míquel, Juan Ramón Larrubia

### Abstract

Chronic hepatitis B (CHB) remains a challenging global health problem, with nearly one million related deaths per year. Nucleos(t)ide analogue (NA) treatment suppresses viral replication but does not provide complete cure of the hepatitis B virus (HBV) infection. The accepted endpoint for therapy is the loss

### Match Overview

1	Internet 89 words crawled on 01-Nov-2016 <a href="http://www.wjnet.com">www.wjnet.com</a>	2%
2	Internet 25 words crawled on 05-Dec-2014 <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>	1%
3	Internet 17 words crawled on 10-Mar-2016 <a href="http://cdn.intechopen.com">cdn.intechopen.com</a>	<1%

找到约 103,000 条结果 (用时 0.65 秒)

### Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who ...

<https://www.sciencedirect.com/science/article/pii/S2542568417000319> - 翻译此页

作者: SGR Kho-Herman - 2017 - 相关文章

Nucleos(t)ide analogs (NAs) are one of the first-line treatments for chronic hepatitis B (CHB) infection. NAs are ..... patients showed 45.3% of patients developed clinical relapse (HBV DNA levels >2000 IU/ml and ALT levels >2 times the upper limit of normal) 1 year after stopping entecavir according to the APASL criteria.

### [Is it possible to stop nucleos(t)ide analogue based therapy in chronic ...

<https://www.ncbi.nlm.nih.gov/pubmed/18662610> - 翻译此页

作者: JP Bronowicki - 2008 - 被引用次数: 1 - 相关文章

Nucleos(t)ide analogues are very efficient in the treatment of chronic hepatitis B. In the HBe antigen positive patients, the HBe seroconversion rates range from 12 to 22% after one year of treatment. When HBe seroconversion occurs, it is possible to stop the treatment with analogue but only in non cirrhotic patients.

### Stopping long-term treatment with nucleos(t)ide analogues is a ...

[onlinelibrary.wiley.com/doi/10.1111/liv.13654/full](https://onlinelibrary.wiley.com/doi/10.1111/liv.13654/full) - 翻译此页

2018年2月10日 - Unlike patients with HBeAg-positive chronic hepatitis B (CHB), there are no clearly defined treatment endpoints for those with HBeAg-negative CHB. Current treatment guidelines recommend long-term oral nucleos(t)ide analogue(NA) therapy until immunological control is established, which is believed to ...

### Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who ...

[https://www.researchgate.net/.../319437218\\_Stopping\\_nucleostide\\_analog\\_tr...](https://www.researchgate.net/.../319437218_Stopping_nucleostide_analog_tr...) - 翻译此页

Request (PDF) | Stopping nucleos(t)i... | Nucleos(t)ide analogs (NAs) are one of the first-line treatments for chronic hepatitis B (CHB) infection. ... Furthermore, there is no consensus regarding in whom and when to restart treatment among patients with hepatitis relapse after stopping NA therapy. Recent studies suggest that ...

### [PDF] Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B ...





Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis



全部

图片

新闻

购物

视频

更多

设置

工具

找到约 143,000 条结果 (用时 0.59 秒)

小提示: 仅限搜索简体中文结果。您可以在设置中指定搜索语言

### Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who ...

<https://www.sciencedirect.com/science/article/pii/S2542568417000319> - 翻译此页

作者: SGR Kho-Herman - 2017 - 相关文章

Nucleos(t)ide analogs (NAs) are one of the first-line treatments for chronic hepatitis B (CHB) infection. NAs are ..... patients showed 45.3% of patients developed clinical relapse (HBV DNA levels >2000 IU/ml and ALT levels >2 times the upper limit of normal) 1 year after stopping entecavir according to the APASL criteria.

### Stopping long-term treatment with nucleos(t)ide analogues is a ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29427489> - 翻译此页

作者: F van Bömmel - 2018 - 被引用次数: 1

Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. ... immune control in some patients which may result in HBsAg loss or a form of immune control, then sustained low HBV DNA levels and normal alanine aminotransferase (ALT).

### [Is it possible to stop treatment with nucleos(t)ide analogs in patients ...

<https://www.ncbi.nlm.nih.gov/pubmed/25636371> - 翻译此页

作者: MRM Martín - 2015

Gastroenterol Hepatol. 2015 May;38(5):305-12. doi: 10.1016/j.gastrohep.2014.12.001. Epub 2015 Jan 27. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations]. [Article in Spanish]. Martín Mateos RM(1), Moreira Vicente VF(2), ...

### [Is it possible to stop nucleos(t)ide analogue based therapy in chronic ...

<https://www.ncbi.nlm.nih.gov/pubmed/18662610> - 翻译此页

作者: JP Bronowicki - 2008 - 被引用次数: 1 - 相关文章

Nucleos(t)ide analogues are very efficient in the treatment of chronic hepatitis B. In the HBe antigen positive patients, the HBe seroconversion rates range from 12 to 22% after one year of treatment. When HBe seroconversion occurs, it is possible to stop the treatment with analogue but only in non

[全部](#)[图片](#)[新闻](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 430,000 条结果 (用时 0.57 秒)

### Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who ...

<https://www.sciencedirect.com/science/article/pii/S2542568417000319> - 翻译此页

作者: SGR Kho-Herman - 2017 - 相关文章

Nucleos(t)ide analogs (NAs) are one of the first-line treatments for chronic hepatitis B (CHB) infection. NAs are ..... patients showed 45.3% of patients developed clinical relapse (HBV DNA levels >2000 IU/ml and ALT levels >2 times the upper limit of normal) 1 year after stopping entecavir according to the APASL criteria.

### Stopping long-term treatment with nucleos(t)ide analogues is a ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29427489> - 翻译此页

作者: F van Bömmel - 2018 - 被引用次数: 1

Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. ... immune control in some patients which may result in HBsAg loss or a form of immune control, then sustained low HBV DNA levels and normal alanine aminotransferase (ALT).

### [Is it possible to stop nucleos(t)ide analogue based therapy in chronic ...

<https://www.ncbi.nlm.nih.gov/pubmed/18662610> - 翻译此页

作者: JP Bronowicki - 2008 - 被引用次数: 1 - 相关文章

Nucleos(t)ide analogues are very efficient in the treatment of chronic hepatitis B. In the HBe antigen positive patients, the HBe seroconversion rates range from 12 to 22% after one year of treatment. When HBe seroconversion occurs, it is possible to stop the treatment with analogue but only in non cirrhotic patients.

您 18-3-31 访问过该网页。

### [PDF] ide analogue treatment in Caucasian hepatitis B patients after HBeA...

<https://repository.uantwerpen.be/docman/irua/0cb4a8/149024.pdf> - 翻译此页

作者: S Van Hees - 2018

of chronic hepatitis B patients with nucleos(t)ide analogue-induced HBeAg seroconversion. Methods: This ... Of the 62 patients who stopped treatment after a median con- ..... ULN, Upper Limit of Normal (40 IU/mL); SC, Seroconversion; NA, nucleos(t)ide Analogues: /, not applicable; FU, follow-up; ALT, alanine aminotrans-